EnamineStore Blog

From the Flask

Larotrectinib Retrosynthesis

   by Yehor Malets  
Larotrectinib Retrosynthesis

Larotrectinib (VITRAKVI®, Loxo Oncology Inc. and Bayer) is an inhibitor of receptors TrkA, TrkB, and TrkC which was approved by FDA for adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, that are either metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory alternative treatments or whose cancer has progressed following treatment on November 26, 2018.

Lofexidine Retrosynthesis

   by Yehor Malets  
Lofexidine Retrosynthesis

Lofexidine (Lucemyra®, US Woldmeds LLC) is a medication historically used to treat high blood pressure which was approved by FDA as a first non-opioid drug for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults on May 16, 2018. Lucemyra is not a treatment for opioid use disorder (OUD), but can be used as part of a broader, long-term treatment plan for managing OUD.